Identifying risk individuals for heart failure diagnosis within two years in the adult population in southern Sweden using gender, age, multimorbidity level, and socioeconomic status

• by Mia Scholten, Anders Halling

• July 6, 2026

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

• by Kathryn Wighton

• July 16, 2026

• 6 min

Validation of femoral pressure-derived assessment of effective arterial elastance in porcine ischemic cardiogenic shock

• by Oskar Kjærgaard Hørsdal, Nigopan Gopalasingam, Kristoffer Berg-Hansen, Roni Nielsen

• July 21, 2026

Long-term SGLT2 inhibitor therapy improves myocardial strain and diastolic function in HFpEF: a retrospective study linking functional recovery to reduced myocardial fibrosis

• by Xiaojin Xu, Hongyang Liu, Runyang Chen

• July 21, 2026